Aptose Biosciences Inc. financial data

Symbol
APTO on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
66 Wellington Street West, Suite 5300, Td Bank Tower Box 48, Toronto, Ontario, Canada
State of incorporation
Ontario, Canada
Fiscal year end
December 31
Former names
Aptose Biosciences Inc., (formerly LORUS THERAPEUTICS INC.) (to 11/26/2014), LORUS THERAPEUTICS INC (to 9/2/2014), IMUTEC PHARMA INC (to 3/24/1998)
Latest financial report
Q1 2024 - May 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 133 % -71.8%
Debt-to-equity 290 % +941%
Return On Equity -1 K % -847%
Return On Assets -258 % -211%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 15.7 M shares -83.1%
Common Stock, Shares, Outstanding 15.7 M shares -83.1%
Entity Public Float 29.6 M USD -56.7%
Common Stock, Value, Issued 450 M USD +2.86%
Weighted Average Number of Shares Outstanding, Basic 13.1 M shares +113%
Weighted Average Number of Shares Outstanding, Diluted 13.1 M shares +113%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 30.9 M USD +19.1%
General and Administrative Expense 13.6 M USD -13.2%
Nonoperating Income (Expense) 849 K USD -28.1%
Net Income (Loss) Attributable to Parent -47.2 M USD -7.16%
Earnings Per Share, Basic -6.33 USD/shares +12.2%
Earnings Per Share, Diluted -6.33 USD/shares +12.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.35 M USD -67.7%
Cash, Cash Equivalents, and Short-term Investments 9.3 M USD -74%
Other Assets, Current 674 K USD +316%
Assets, Current 11.8 M USD -68.8%
Property, Plant and Equipment, Net 125 K USD -31.7%
Operating Lease, Right-of-Use Asset 850 K USD -30.2%
Assets 12.8 M USD -67.5%
Accounts Payable, Current 2.42 M USD -56.1%
Employee-related Liabilities, Current 1.14 M USD -3.05%
Accrued Liabilities, Current 9.32 M USD +41.3%
Liabilities, Current 12.1 M USD -2.26%
Operating Lease, Liability, Noncurrent 520 K USD -43.4%
Liabilities 12.7 M USD -5.08%
Accumulated Other Comprehensive Income (Loss), Net of Tax -4.32 M USD -0.07%
Retained Earnings (Accumulated Deficit) -525 M USD -9.87%
Stockholders' Equity Attributable to Parent 137 K USD -99.5%
Liabilities and Equity 12.8 M USD -67.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -45.1 M USD -32.6%
Net Cash Provided by (Used in) Financing Activities 18.7 M USD +12289%
Net Cash Provided by (Used in) Investing Activities 10.9 M USD -44.2%
Common Stock, Shares, Issued 15.7 M shares -83.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -15.4 M USD -8.34%
Deferred Tax Assets, Valuation Allowance 91.3 M USD +16.7%
Deferred Tax Assets, Gross 91.3 M USD +16.7%
Operating Lease, Liability 919 K USD -24.9%
Payments to Acquire Property, Plant, and Equipment 29 K USD +20.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -47.2 M USD -7.18%
Lessee, Operating Lease, Liability, to be Paid 1 M USD -28.1%
Property, Plant and Equipment, Gross 801 K USD -14.9%
Operating Lease, Liability, Current 399 K USD +30.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 197 K USD -57.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 462 K USD +0.65%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, to be Paid, Year Three 198 K USD
Deferred Tax Assets, Operating Loss Carryforwards 73.6 M USD +22.4%
Operating Lease, Payments 392 K USD -26.2%
Additional Paid in Capital 79.1 M USD +12.5%
Depreciation, Depletion and Amortization 76 K USD -34.5%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 2.59 M USD -43.3%